Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Tax Provisions (2023 - 2025)

Monte Rosa Therapeutics' Tax Provisions history spans 3 years, with the latest figure at $59000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 97.27% year-over-year to $59000.0; the TTM value through Dec 2025 reached -$1.1 million, down 142.4%, while the annual FY2025 figure was -$1.1 million, 142.68% down from the prior year.
  • Tax Provisions reached $59000.0 in Q4 2025 per GLUE's latest filing, up from -$3.2 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.2 million in Q4 2024 to a low of -$3.2 million in Q3 2025.
  • Average Tax Provisions over 3 years is $166181.8, with a median of $170000.0 recorded in 2023.
  • Peak YoY movement for Tax Provisions: soared 9936.36% in 2024, then plummeted 4574.65% in 2025.
  • A 3-year view of Tax Provisions shows it stood at -$22000.0 in 2023, then skyrocketed by 9936.36% to $2.2 million in 2024, then tumbled by 97.27% to $59000.0 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Tax Provisions are $59000.0 (Q4 2025), -$3.2 million (Q3 2025), and $1.2 million (Q2 2025).